Epithelial ovarian cancer cell viability has been shown to be dependent on EZH2 expression, and therefore, EZH2 inhibition, is a promising targeted therapeutic strategy [46], highlighting the potential of miR-101 in the treatment of epithelial ovarian cancer. The gene discussed is EZH2; the disease is ovarian carcinoma.